Document Type : Original Article
Authors
1 General Surgery, ESIC-PGIMSR and Model Hospital Basaidarapur, New Delhi, India
2 Department of General Surgery, ESIC-PGIMSR and Model Hospital, Basaidarapur, News Delhi, India
Abstract
Objective: Perforation peritonitis is a common surgical emergency which is treated by
surgery and antibiotics. Candida isolation in peritoneal fluid and antifungal treatment is
not a norm. The aim of this study was to determine the incidence of Candida in peritoneal
fluid and its role in the outcome of patients with perforation peritonitis.
Methods: This prospective observational study was conducted on 70 patients with
perforation peritonitis from October 2016 to February 2018. Intraoperatively, peritoneal
fluid was taken and sent for microbiological culture and sensitivity. Perforation was
managed according to the site of perforation and condition of bowel.
Results: The mean age of the patients was 38.74 years with male predominance (58,
82.85%). Forty-seven (67.14%) patients had positive peritoneal cultures. Escherichia coli
was the most common bacteria (n=29), while Candida was found to be the most common
fungi and was found in 18 patients. The incidence of Candida was higher in upper gastroduodenal perforation (30, 42.85%). Patients found positive for Candida had APACHE II
severity score 10 or more which was higher than the rest of the patients. The mortality was
higher in patients with positive peritoneal cultures (10/47) as compare to negative ones
(2/23, P<0.001). The mortality in mixed bacterial and fungal-positive cultures (7/18) was
also higher as compared to isolated bacterial culture (3/29, P <0.001). The overall mortality
rate was 17.14%.
Conclusion: Patients with Candida positive peritoneal culture had a significant mortality
and morbidity as compared to Candida negative. Peritoneal fluid culture and sensitivity for
bacterial and fungal were helpful in the early diagnosis and treatment
Keywords
- Perforation peritonitis
- Candida
- Fungal peritonitis
- Outcome
- Primary peritonitis
- Abdominal cavity
- Laparotomy
Main Subjects
- Carneiro HA, Mavrakis A, Mylonakis E. Candida peritonitis: an update on the latest research and treatments.
World J Surg 2011; 35(12): 2650-9. doi: 10.1007/s00268-011-1305-2.
2. Shan YS, Hsu HP, Hsieh YH, Sy ED, Lee JC, Lin PW. Significance of intraoperative peritoneal culture of fungus
in perforated peptic ulcer. Br J Surg 2003; 90(10): 1215-9.doi: 10.1002/bjs.4267.
3. Lee SC, Fung CP, Chen HY, Li CT, Jwo SC, Hung YB, et al. Candida peritonitis due to peptic ulcer perforation:
incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect
Dis 2002; 44(1): 23-7. doi: 10.1016/s0732-8893(02)00419-4.
4. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be
predicted in intensive care unit patients with peritonitis?Crit Care Med 2003; 31(3): 752-7. doi: 10.1097/01.
ccm.0000053525.49267.77.
5. Montravers P, Dupont H, Eggimann P. Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic
invasive candidiasis. Intensive Care Med 2013; 39(12): 2226-30. doi: 10.1007/s00134-013-3134-2.
6. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline
for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis
2016; 62(4): e1-50. doi: 10.1093/cid/civ933.
7. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the
diagnosis and management of Candida diseases 2012: nonneutropenic adult patients. Clin Microbiol Infect 2012; 18
Suppl 7: 19-37. doi: 10.1111/1469-0691.12039.
8. Pramod J, Vijayakumar C, Srinivasan K, Maroju NK, Raj Kumar N, Balasubramaniyan G. Clinical significance of
Candida in an intraoperative peritoneal specimen with perforation peritonitis: an institutional perspective. Cureus
2018; 10(3): e2275. doi: 10.7759/cureus.2275.
9. Prakash A, Sharma D, Saxena A, Somashekar U, Khare N, Mishra A, et al. Effect of Candida infection on outcome in
patients with perforation peritonitis. Indian J Gastroenterol 2008; 27(3): 107-9.
10. Jindal N, Arora S, Pathania S. Fungal culture positivity in patients with perforation peritonitis. J Clin Diagn Res 2015;
9(6): DC01-3. doi: 10.7860/jcdr/2015/13189.6050.
11. Zhan J, Shu G, Yuan L, Zhu J, Xie B. Clinical features of fungal peritonitis with Candida albicans infection after
gastric and duodenal perforation. Emerg Med (Los Angel) 2015; 5(4): 264. doi: 10.4172/2165-7548.1000264.
12. Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, et al. A randomized, placebo-controlled
trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for
intra-abdominal infections. Clin Infect Dis 2015; 61(11): 1671-8. doi: 10.1093/cid/civ707.
13. Johnson DW, Cobb JP. Candida infection and colonization in critically ill surgical patients. Virulence 2010; 1(5): 355-6.doi: 10.4161/viru.1.5.13254.
14. Hsu FC, Lin PC, Chi CY, Ho MW, Ho CM, Wang JH. Prognostic factors for patients with culture-positive
Candida infection undergoing abdominal surgery. J Microbiol Immunol Infect 2009; 42(5): 378-84.
15. Dupont H, Guilbart M, Ntouba A, Perquin M, Petiot S, Regimbeau JM, et al. Can yeast isolation be predicted in
complicated secondary non-postoperative intra-abdominal infections? Crit Care 2015; 19(1): 60. doi: 10.1186/s13054-
015-0790-3.
16. Katlana A, Vyas AK, Jain R, Rathi A, Sharma NK, Yadav AK, et al. Incidence and significance of intra-operative peritoneal fluid fungal culture in patients of perforated peptic ulcers. J Med Sci Clin Res 2017; 5(3): 18987-91. doi:
10.18535/jmscr/v5i3.110.
17. Bassetti M, Merelli M, Ansaldi F, de Florentiis D, Sartor A, Scarparo C, et al. Clinical and therapeutic aspects of
candidemia: a five year single centre study. PLoS One 2015; 10(5): e0127534. doi: 10.1371/journal.pone.0127534.
18. Bassetti M, Righi E, Montravers P, Cornely OA. What has changed in the treatment of invasive candidiasis? a look at
the past 10 years and ahead. J Antimicrob Chemother 2018;73(Suppl 1): i14-i25. doi: 10.1093/jac/dkx445.
19. Vergidis P, Clancy CJ, Shields RK, Park SY, Wildfeuer BN, Simmons RL, et al. Intra-abdominal candidiasis:
the importance of early source control and antifungal treatment. PLoS One 2016; 11(4): e0153247. doi: 10.1371/
journal.pone.0153247.
20. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, et al. Timing of susceptibility-based antifungal drug
administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 2012; 67(3): 707-14. doi: 10.1093/jac/dkr511.
21. Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, et al. Empirical micafungin treatment
and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and
multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA 2016; 316(15): 1555-64. doi: 10.1001/
jama.2016.14655 - .22. Khoury W, Szold O, Soffer D, Kariv Y, Wasserlauf R, Klausner JM, et al. Prophylactic fluconazole does not
improve outcome in patients with purulent and fecal peritonitis due to lower gastrointestinal perforation. Am
Surg 2010; 76(2): 197-202.
23. Li WS, Lee CH, Liu JW. Antifungal therapy did not improve outcomes including 30-day all-cause mortality in patients suffering community-acquired perforated peptic ulcerassociated peritonitis with Candida species isolated from their peritoneal fluid. J Microbiol Immunol Infect 2017;50(3): 370-6. doi: 10.1016/j.jmii.2015.07.004.
24. Montravers P, Perrigault PF, Timsit JF, Mira JP, Lortholary O, Leroy O, et al. Antifungal therapy for patients with
proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units.
Clin Microbiol Infect 2017; 23(2): 117.e1-117.e8. doi:10.1016/j.cmi.2016.10.001.
)